# Sironax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sironax

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.sironax.com
- Total disclosed funding: $200M
- Latest round: Series B (Aug 2, 2022)
- Investors on record: 15

## About

Established in 2017 and based in Beijing, China, Sironax Ltd. is a biotechnology company focused on developing new therapies for patients with degenerative diseases of the elderly. The company operates in China and the United States and has approximately 180 employees. Previously, the company completed nominations, healthy subjects and patient studies for its lead development drug SIR0365 by 2020, and opened a second Ph1b study in 2021. The company's chairman and co-founder, Dr. Xiaodong Wang has been a member of the U.S. National Academy of Sciences since 2004 and a foreign member of the Chinese Academy of Sciences since 2013, and also co-founded Baji Shenzhou. 

In September 2019, Sironax raised USD 101 million in Series A funding from new investor F-Prime Capital. Additionally, in August 2022, Sironax raised USD 200 million in Series B funding co-led by Gaorong Capital and YF Capital, with participation from CBC Group, Life Science Vision Capital, LRVHealth, MSA Capital, Superstring Capital Management, Future Qichuang Capital, Abu Dhabi Investment Authority, ARCH Venture Partners, Eight Roads Ventures, F-Prime Capital, Invus, K2VC, and Temasek Holdings.

Sironax focuses on the development and production of inhibitors, with a research pipeline consisting of multiple programs targeting the regulation of cell death, neuroprotective pathways and neuroinflammation. The pipeline contains seven innovative programs spanning small and large molecules, with the main RIPK1 program consisting of several chemically differentiated small molecule inhibitors, including SIR0365 and SIR2446.

The company plans to use the 2022 funding to support the continued clinical development of the Company's portfolio of receptor-interacting serine/threonine protein kinase 1 (RIPK1) inhibitors, in addition to continuing to expand its development footprint and potential best-in-class and first-in-class pipeline - candidates for age-related degenerative diseases.

## Funding rounds

- Series B, Aug 2, 2022, $200M — ARCH Venture Partners, Eight Roads Ventures, Invus [DUP], F-Prime Capital, Abu Dhabi Investment House, Temasek Holdings, YF Capital, MSA Capital, Gaorong Ventures, CBC Group, K2VC, Superstring Capital Management, Future Qichuang Capital, Life Science Vision Capital, LongRiver Investments

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- Invus [DUP] — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Abu Dhabi Investment House (https://capitalatlas.ai/funds/abu-dhabi-investment-house) — Series B
- Temasek Holdings — Series B
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series B
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series B
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series B
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series B
- Future Qichuang Capital (https://capitalatlas.ai/funds/future-qichuang-capital) — Series B
- Life Science Vision Capital (https://capitalatlas.ai/funds/life-science-vision-capital) — Series B
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Series B